Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014

Description:

DelveInsights, Fatty Liver Disease-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fatty Liver Disease. – PowerPoint PPT presentation

Number of Views:44
Slides: 15
Provided by: addyparker2350

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014


1
Fatty Liver Disease-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/healthcare/77058/-fatty-l
    iver-disease-pipeline-insights-2014

2
Summary
  • DelveInsights, Fatty Liver Disease-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    indication. A key objective of the report is to
    establish the understanding for all the pipeline
    drugs that fall under Fatty Liver Disease. This
    report provides information on the therapeutic
    development based on the Fatty Liver Disease
    dealing with all the pipeline drugs, comparative
    analysis at various stages covering Filed, Phase
    III, Phase II, Phase I, IND filed, Preclinical,
    Discovery and unknown stages, therapeutics
    assessment by monotherapy and combination
    products and molecule type drug information. The
    report also covers the companies information
    involved in the therapeutic development of the
    products. It also has highlighted the
    discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts. Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases. Note This report requires
    certain updates. We have all the information
    available but require 3 business days to complete
    the process and ensure it is as up-to-date as
    possible. Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated Indication.

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Fatty Liver Disease The
    report provides pipeline products under drug
    profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    information Coverage of the Fatty Liver Disease
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    type The report reviews key players involved in
    the therapeutics development for Fatty Liver
    Disease and also provide company profiling The
    report also gives the information of dormant and
    discontinued pipeline projects  Pipeline products
    coverage based on various stages of development
    ranging from preregistration till discovery and
    undisclosed stages  Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buy Complete Pipeline intelligence
    and complete understanding over therapeutics
    development for Fatty Liver Disease Identify the
    relationship between the drugs and use it for
    target finding, drug repurposing, and precision
    medicine. Devise corrective measures for pipeline
    projects by understanding Fatty Liver Disease
    pipeline depth and focus of Indication
    therapeutics  Developing strategic initiatives to
    support your drug development activities. Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope Provides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies  Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipeline Gaining a Full Picture of the
    Competitive Landscape for Evidence based Decisions

7
Table of Content
  • Fatty Liver Disease Overview Fatty Liver Disease
    Pipeline Therapeutics Fatty Liver Disease
    Therapeutics under Development by
    Companies  Fatty Liver Disease Late Stage
    Products (Filed and Phase III) Comparative
    Analysis  Fatty Liver Disease Mid Clinical Stage
    Products (Phase II) Comparative Analysis  Fatty
    Liver Disease Early Clinical Stage Products
    (Phase I and IND Filed) Comparative
    Analysis  Fatty Liver Disease Discovery and
    Pre-Clinical Stage Products  Comparative
    Analysis  Drug Candidate Profiles

8
Table of Content
  • Fatty Liver Disease Therapeutics
    Assessment  Assessment by Monotherapy
    Products  Assessment by Combination
    Products  Assessment by Route of
    Administration  Assessment by Molecule
    Type  Fatty Liver Disease Discontinued
    Products  Fatty Liver Disease Dormant
    Products Companies Involved in Therapeutics
    Development for Fatty Liver Disease  Appendix  Met
    hodology  Contact Us  Disclaimer

9
List of Tables
  • Number of Products under Development for Fatty
    Liver Disease, 2014 Number of Products under
    Development by Companies  Comparative Analysis by
    Late Clinical Stage Products (Filed and Phase
    III), 2014 Comparative Analysis Mid Clinical
    Stage Products (Phase II), 2014 Comparative
    Analysis Early Clinical Stage Products (Phase I
    and IND Filed), 2014 Comparative Analysis
    Discovery and Pre-Clinical Stage Products,
    2014 Drug Candidates Profiles

10
List of Tables
  • Fatty Liver Disease Assessment by Monotherapy
    Products  Fatty Liver Disease Assessment by
    Combination Products  Fatty Liver Disease
    Assessment by Route of Administration  Fatty
    Liver Disease Assessment by Stage and Route of
    Administration  Fatty Liver Disease Assessment by
    Molecule Type  Fatty Liver Disease Assessment by
    Stage and Molecule Type  Fatty Liver Disease
    Therapeutics Discontinued Products  Fatty Liver
    Disease Therapeutics Dormant Products Products
    under Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for Fatty
    Liver Disease, 2014 Late Clinical Stage Products
    (Filed and Phase III), 2014 Mid Clinical Stage
    Products (Phase II), 2014 Early Clinical Stage
    Products (Phase I and IND Filed), 2014 Discovery
    and Pre-Clinical Stage Products, 2014 Fatty Liver
    Disease Assessment by Monotherapy Products  Fatty
    Liver Disease Assessment by Combination
    Products  Fatty Liver Disease Assessment by Route
    of Administration  Fatty Liver Disease Assessment
    by Stage and Route of Administration  Fatty Liver
    Disease Assessment by Molecule Type  Fatty Liver
    Disease Assessment by Stage and Molecule Type

12
Related Reports
  • The Mobile Healthcare (mHealth) Bible 2014 -
    2020
  • Pregnancy Detection Kit Market in the US
    2015-2019
  • Global Prenatal and Newborn Genetic Testing
    Market 2015-2019
  • Global Knee Implant market 2015-2019
  • Global Isosorbide Market 2015-2019
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Fatty Liver Disease-Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights, Fatty Liver Disease-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    indication.
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com